Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/19/2021 | Outperform → Market Perform | Northland Capital Markets | |
| 10/19/2021 | $25.00 → $10.00 | Buy → Neutral | HC Wainwright & Co. |
| 10/12/2021 | $20.00 → $12.00 | Outperform → Market Perform | BMO Capital |
| 10/12/2021 | Strong Buy → Market Perform | Raymond James | |
| 10/12/2021 | $14.00 → $10.00 | Outperform → Neutral | Credit Suisse |
| 8/6/2021 | $8.00 → $6.00 | Neutral | Goldman Sachs |
| 8/5/2021 | $20.00 → $18.00 | Buy | Needham |
Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions. This press release features multimedia. View the full release here: https://www.busi
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the completion of its previously announced acquisition of Flexion Therapeutics, Inc. (NASDAQ:FLXN). "This is an exciting day for Pacira BioSciences as this acquisition expands our industry leadership and marks a major milestone in our strategy to build a robust offering of novel, non-opioid treatments to im
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced a definitive agreement
Northland Capital Markets downgraded Flexion Therapeutics from Outperform to Market Perform
HC Wainwright & Co. downgraded Flexion Therapeutics from Buy to Neutral and set a new price target of $10.00 from $25.00 previously
BMO Capital downgraded Flexion Therapeutics from Outperform to Market Perform and set a new price target of $12.00 from $20.00 previously
4 - Flexion Therapeutics Inc (0001419600) (Issuer)
3 - Flexion Therapeutics Inc (0001419600) (Issuer)
4 - Flexion Therapeutics Inc (0001419600) (Issuer)
15-12B - Flexion Therapeutics Inc (0001419600) (Filer)
EFFECT - Flexion Therapeutics Inc (0001419600) (Filer)
S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)
SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)
SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)
Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions. This press release features multimedia. View the full release here: https://www.busi
BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion's audit committee. "I am thrilled to welcome Utpal to Flexion's Board, as his extensive financial experience leading biotechnology companies makes him an outstanding addition to our Board of Directors," said Michael Clayman, MD, President and Chief Executive Officer of Flexion Therapeutics. "In addition to Utpal's anticipated contributions guiding our corporate strategy, I look forward to his stewardship and counsel as chai
BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021. "Will brings an impressive combination of medical, clinical, regulatory and corporate development skills, complemented by deep commercial experience he gained launching seven products throughout his career,” said Michael Clayman, MD, President and Chief Executive Officer of Flexion Therapeutics. “He will play an integral role in building and strengthening our organization, and we could not be more excited to welcome him to our senior management team.” "I have be
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced a definitive agreement
ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarterNet loss in Q2 2021 decreased by $10.4 million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on ZILRETTA salesCompany extends estimated cash runway into 2023 by refinancing term loanFlexion reiterates full-year 2021 ZILRETTA net sales guidance in the range of $120 million to $130 millionData for FX301 bunionectomy study and FX201 single ascending dose/expansion knee osteoarthritis (OA) study anticipated by year-endConference call to be held today at 4:30 pm BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEW
BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET. A live webcast of the conference call can be accessed through the "Investors" tab on the Flexion Therapeutics website, and a replay will be available online after the call. For those planning to ask a question, the dial-in number for the conference call is 855-770-0022 for domestic participants and 908-982-4677 for international participants, with Conference ID # 3846257. Please dial in at least 15 minutes in advance to ensure